You are currently viewing Sports Betting and Biotech Dominate the Markets

Sports Betting and Biotech Dominate the Markets

Welcome back to Bullish Rippers! Volatility in the market is coming back down to Earth after a wild last few weeks of trading. Markets ripped upwards to the tune of 1% gains in trading today. Our Rippers list today is dedicated to the bettors and the pharma nerds out there — filled with sports betting and biotech winners. Let’s see what investors are putting money on:

💊 It’s now officially M&A SZN in the pharma space, and Immunomedics just became one of the biggest acquisitions of the year. Pharma giant Gilead agreed to acquire $IMMU for $21 billion. Along with that acquisition, $GILD is securing Trodelvy, a promising new cancer drug approved by the FDA in April which made $20 million in its first 60 days on the market. Trodelvy’s blockbuster beginnings are set to continue as Gilead tests the drug in new indications. $IMMU is up 98% on the news.

🏈 A leader in the online sports betting market is gaining traction today. DraftKings announced an integration with sports broadcast giant ESPN. The announcement makes $DKNG the “exclusive provider of daily fantasy sports and co-exclusive partner for gambling link-outs,” according to the entertainment giant. The deal means $DKNG is going to be involved in meaningful activations on the network. The news adds 17% today to a meteoric 355% rise in 2020.

🥇DraftKings isn’t the only sportsbook making moves. Penn National Gaming is coming with similarly impressive gains in trading today. $PENN is up nearly 11% today as analysts recommended buying the casino company. Earlier this year, we covered $PENN making the move into media after they acquired a considerable sum of Barstool Sports. Barstool already commands considerable influence over sports culture, so its potential to scale the sports betting service might represent radical potential.

🏠 Today in weird emerging market politics: a Chinese real estate developer is experiencing a hostile takeover at the hands of one of its largest shareholders. $NTP is up 18% after IsZo Capital, which owns 10% of the company, announced its intention to nominate a new board of directors who will prioritize shareholder causes. The director of the real estate company resigned shortly after the special meeting was called. It’s a unique departure from the kind of stories we typically see on our list, seeing as though this is notably not positive for the current board. However, shareholders are singing to a different tune.

🧪 Two other biotech companies stood out on today’s list: the bizarrely named Applied Molecular Transport began dosing for its mid-stage clinical drug for ulcerative colitis. On the flip, the very ‘new age’ sounding biotech Turning Point Therapeutics received accelerated approval from the FDA for its cancer drug repotrectinib. $AMTI and $TPTX are both up 13% today.

That’s a wrap on our Monday Rippers list. Check back on Wednesday to get the scoop on what’s moving 📈📈📈

Bullish Staff

Words from the whole team here at Bullish. We're starting a new conversation about money with the greatest investors and most existing creators.

Leave a Reply